AlloVir(ALVR)
搜索文档
AlloVir(ALVR) - 2024 Q3 - Quarterly Report
2024-11-13 05:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________to __________________ Commission File Number: 001-39409 ALLOVIR, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 83 ...
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of AlloVir, Inc. – ALVR
GlobeNewswire News Room· 2024-11-09 01:29
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating AlloVir, Inc. (NASDAQ: ALVR), relating to its proposed merger with Kalaris Therapeutics. Under the terms of the agreement, AlloVir will acquire 100% of the outstanding equity interest of ...
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
GlobeNewswire News Room· 2024-11-08 19:00
Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases Invented by VEGF pioneer Dr. Napoleone Ferrara, TH103 has demonstrated longer-acting and increased anti-VEGF activity in head-to-head preclinical studies against aflibercept, and could potentially provide a meaningful advance in treatment in the global $14 billion br ...
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm
GlobeNewswire News Room· 2024-09-16 23:16
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of AlloVir, Inc. (NASDAQ: ALVR) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, AlloVir insiders caused the company to misrepresent or fail to disclose that (i) the posoleucel Phase 3 Studies were unlikely to meet their primary endpoints; (ii) as a result, it was likely that the company would ultimately discontinu ...
AlloVir(ALVR) - 2024 Q2 - Quarterly Report
2024-08-09 21:05
公司战略调整 - 公司宣布终止三项第三期注册试验,因为独立数据安全监测委员会的中期分析结果表明这些试验很可能无法达到主要终点指标[108] - 公司将对这些第三期试验的详细数据进行审查,并启动全面的战略替代方案评估,包括并购、出售、资产剥离、许可或其他战略交易[109] - 公司暂停了ALVR106和ALVR107的临床开发,正在等待战略替代方案评估的结果[110] 公司运营情况 - 公司已实施裁员约95%的计划,以最大限度地保留资本[109] - 公司自成立以来一直专注于筹资、组建团队、业务规划、研发以及知识产权保护等工作,尚未获得任何产品批准或实现产品销售收入[111] - 公司通过多次股权融资获得了总计约4.89亿美元的资金[112][113][114] - 截至2024年6月30日,公司拥有1.296亿美元的现金、现金等价物和短期投资,但管理层认为公司存在持续经营的重大不确定性[116][120] - 如果恢复产品候选药的开发,公司预计未来会持续发生大量研发支出和运营亏损[118][119] - 新冠疫情可能会对公司的临床试验和供应链造成干扰[121][122] 财务数据 - 公司研发费用在2024年第二季度下降至0.1百万美元,较2023年同期的34.8百万美元大幅下降34.7百万美元[138] - 公司一般及行政费用在2024年第二季度下降至7.2百万美元,较2023年同期的12.5百万美元下降5.3百万美元[139] - 公司在2024年第二季度发生了0.5百万美元的重组成本,主要为裁员相关的离职补偿[140] - 公司在2024年上半年发生了10.0百万美元的重组成本,主要为裁员相关的离职补偿[146] - 公司在2024年6月30日的现金、现金等价物和短期投资为129.6百万美元[150] - 公司认为现有现金、现金等价物和短期投资将使其能够维持至少12个月的运营费用和资本支出要求[150] - 公司预计研发费用将继续大幅下降,但如果未来恢复产品候选物的开发,研发费用将显著增加[151,152] - 公司未来的资金需求将取决于多个因素,包括产品开发进度、监管审批、商业化活动等[153] - 公司预计未来将通过股权融资、债务融资等方式筹集资金,以支持业务发展[154] - 2024年6月30日结束的6个月内经营活动产生的净现金流出为5570万美元,主要反映了3640万美元的净亏损和2190万美元的净营运资产和负债减少[156] - 2023年6月30日结束的6个月内经营活动产生的净现金流出为5920万美元,主要反映了8650万美元的净亏损[157] - 2024年6月30日结束的6个月内经营活动产生的净现金流出较2023年同期减少350万美元,主要由于2023年12月宣布终止3项III期注册试验导致的营运资产和负债变化[158] - 2024年6月30日结束的6个月内投资活动产生的净现金流入为7000万美元,主要由于7000万美元的投资到期[159] - 2023年6月30日结束的6个月内投资活动产生的净现金流入为7960万美元,主要由于9380万美元的投资到期[160] - 2024年6月30日结束的6个月内筹资活动产生的净现金流入为0美元,主要由于员工股票购买计划的收益[161] - 2023年6月30日结束的6个月内筹资活动产生的净现金流入为7050万美元,主要由于7020万美元的公开发行普通股净收益[161] 其他合同义务 - 公司在2024年6月30日的经营租赁义务为1100万美元,2024年7月公司与出租方终止了租赁协议并支付了700万美元的违约金[162] - 公司与CRO和其他第三方供应商签有临床试验、检测和制造服务的合同,其中包含采购承诺或其他不可撤销的义务[163] - 公司可能需要根据许可和授权协议支付与临床、监管和商业里程碑相关的或有付款,或支付特许权使用费,但由于事件发生的不确定性,这些金额目前无法确定[163]
AlloVir(ALVR) - 2024 Q1 - Quarterly Report
2024-05-14 04:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________to __________________ Commission File Number: 001-39409 ALLOVIR, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 83-197 ...
AlloVir(ALVR) - 2023 Q4 - Annual Report
2024-03-15 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39409 ALLOVIR, INC. (Exact name of Registrant as specified in its Charter) Delaware 83-1971007 (State or other jurisdiction of incorp ...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir
Newsfilter· 2024-03-01 22:30
NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) and reminds investors of the March 19, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir ...
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
Zacks Investment Research· 2024-01-29 23:41
公司表现 - AlloVir, Inc. 是医疗行业中的一家公司,目前在 Zacks Sector Rank 中排名第8位[2] - AlloVir, Inc. 目前的 Zacks Rank 为 2 (Buy),表明该公司有可能在未来一到三个月内表现优于整个市场[3] - ALVR 过去一个季度的全年盈利预期已经上升了57.9%,显示分析师对该股的情绪正在改善,盈利前景更加积极[4]
Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)
Zacks Investment Research· 2024-01-13 00:19
股票走势分析 - AlloVir, Inc. (ALVR) 最近出现了明显的下降趋势,股票在过去四周下跌了72.4% [1] - RSI是一种常用的技术指标,用于判断股票是否被卖空 [2] - RSI在0到100之间波动,通常当股票的RSI指数低于30时被认为是被卖空的 [3] - RSI有助于快速检查股票价格是否即将出现反转 [4] - ALVR的RSI指数为28.82,表明大量卖出可能正在逐渐消耗,股票可能会反弹 [5] 预期收益和评级 - 分析师们普遍认为ALVR有望报告比之前预测更好的收益,这也是股票可能出现反弹的原因之一 [6] - ALVR目前的Zacks排名为2(买入),这是股票潜在反弹的更具体指标之一 [7]